{ "deterministic": true, "generatedBy": "scripts/easd-2026-study/code.ts codeSaudi() (read-only; inputs listed below)", "protocol": "docs/design/easd-2026-evidence-to-answer-prereg.md (commit 8ee24e19), §9 D10: POST-REGISTRATION arm", "series": { "key": "saudi-t1d", "brand": "Tzield", "market": "Saudi Arabia", "registered": false }, "phase": "baseline", "inputs": { "pull": { "pulledAt": "2026-10-05T13:30:20.369Z", "from": "2026-08-22", "to": "2026-09-26" }, "statusFetchedAt": "2026-10-05T13:22:41.937Z", "manual": "docs/evidence/easd-2026-saudi-manual-codes.json", "manualCoder": "Study coordinator (Claude Opus 5.5): hand-read of every sampled answer, reading the paragraphs that contain the term with their surrounding lines, the full answer opened where the framing was unclear", "manualCodedAt": "2026-10-05" }, "schemeDecisions": [ { "id": "T1", "text": "This arm was added after registration (prereg §9 D10). It is coded by the same scripts and rules as the registered arms but written to its own files, labelled post-registration, and never pooled with a registered figure. The registered outputs iterate the registered series only and are byte-identical whether or not this arm is coded." }, { "id": "T2", "text": "E3 agent set (lib.ts T1D_AGENTS): every named molecule or product presented at EASD 2026 in a type 1 or autoimmune diabetes context, clinical or translational, that holds no marketing authorisation from FDA or EMA for any indication. Sources (EASD Final Programme session and abstract numbers) and each regulator's record: docs/evidence/easd-2026-t1d-agent-set.md, committed before any answer of this arm is coded. Teplizumab is the measured medicine and is never in the set." }, { "id": "T3", "text": "Saudi status. The SFDA register that can be searched (the drugs list) is a POST form behind reCAPTCHA and is not submitted; the Saudi Drug Information site did not complete a TLS handshake. The SFDA list that answers a plain GET (New SFDA Drug Approvals) covers approvals from 1 Feb 2025 to 2 Feb 2026 only. An agent absent from it is therefore 'not-established' in Saudi Arabia, never inferred; by S2's rule a not-established status keeps the agent in scope and marks every code provisional. FDA and EMA records are shown beside it for the reader and never set the Saudi status." }, { "id": "T4", "text": "S3 (what counts as a status statement) and S4 (the which-medicine rule, lib.ts CHOICE_QUESTION) apply unchanged. The clinically material count is the protocol's: status absent or wrong in a which-medicine answer." }, { "id": "T5", "text": "Code 'not-the-agent' removes a term match that does not refer to the agent (e.g. 'BCG' meaning a consultancy, 'HDV' meaning hepatitis D virus, 'Diamyd' naming the company with no reference to its antigen therapy). Such rows are listed in the ledger and excluded from every count." }, { "id": "T6", "text": "E3-i, EXPLORATORY and post-registration (lib.ts T1D_INDICATION_AGENTS): molecules authorised for another indication and presented at EASD 2026 as investigational in type 1 diabetes (sotagliflozin, tirzepatide, semaglutide, BCG, fenofibrate). Codes: indication-stated (the answer says the use in type 1 diabetes is off-label, not approved, investigational, or that the molecule is approved only for another condition); indication-absent (named as an option in type 1 diabetes with no such statement); indication-wrong (presented as approved or indicated for type 1 diabetes); not-a-t1d-use (named for its own indication or a non-type-1 population; not scored); not-the-agent. Exploratory material count: indication-absent or indication-wrong in a which-medicine answer." }, { "id": "T7", "text": "E3-i sampling, fixed before coding: per window and per agent at most 60 naming answers are coded, the lowest ranks of sha256(\"20261005::\"). Unsampled answers are counted as named and shown as NOT-SAMPLED; coded shares carry a Wilson 95% interval." }, { "id": "T8", "text": "Non-programme context (lib.ts T1D_NON_PROGRAMME): type 1 diabetes agents verified ABSENT from the EASD 2026 programme text (zimislecel/VX-880, baricitinib, verapamil, golimumab, abatacept, ladarixin, frexalimab, otelixizumab, anti-thymocyte globulin). Naming answers are counted per engine per cycle, automatically, never coded, and no status is asserted; the count shows what answers name when they do not name the congress's agents." }, { "id": "T9", "text": "E4 and E5 do not apply to this arm (D10). The baseline is capped at 26 Sep (D10, lib.ts BASELINE_CUTOFF_ISO). Prompts must match the first cycle at the rate already recorded (§2), which for this arm is 52 of 56 (D13): four persona-slot questions were reworded after the first cycle (24 Aug) and the 56 questions are identical from 27 Aug to 4 Oct. D12 had transcribed §2 as 54 of 56 (≥ 95%); that is not §2's rule, and it rejected every cycle after the first." } ], "admissions": [ { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 56, "captures": 224 }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 224 }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 221 }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 224 }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 224 }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 223 }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 224 }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 223 }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 220 }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 219 }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "admitted": true, "reasons": [], "promptsCaptured": 56, "promptCount": 56, "promptsMatchingFirst": 52, "captures": 220 } ], "answersPerEngineCycle": { "SA-C01|openai": 56, "SA-C01|anthropic": 56, "SA-C01|google": 56, "SA-C01|perplexity": 56, "SA-C02|openai": 56, "SA-C02|anthropic": 56, "SA-C02|google": 56, "SA-C02|perplexity": 56, "SA-C03|openai": 56, "SA-C03|anthropic": 56, "SA-C03|perplexity": 54, "SA-C03|google": 55, "SA-C04|openai": 56, "SA-C04|anthropic": 56, "SA-C04|google": 56, "SA-C04|perplexity": 56, "SA-C05|openai": 56, "SA-C05|anthropic": 56, "SA-C05|google": 56, "SA-C05|perplexity": 56, "SA-C06|openai": 56, "SA-C06|anthropic": 56, "SA-C06|perplexity": 55, "SA-C06|google": 56, "SA-C07|openai": 56, "SA-C07|anthropic": 56, "SA-C07|google": 56, "SA-C07|perplexity": 56, "SA-C08|openai": 56, "SA-C08|anthropic": 56, "SA-C08|google": 56, "SA-C08|perplexity": 55, "SA-C09|openai": 56, "SA-C09|anthropic": 56, "SA-C09|google": 55, "SA-C09|perplexity": 53, "SA-C10|openai": 56, "SA-C10|anthropic": 56, "SA-C10|google": 56, "SA-C10|perplexity": 51, "SA-C11|openai": 56, "SA-C11|anthropic": 56, "SA-C11|perplexity": 52, "SA-C11|google": 56 }, "headline": { "label": "POST-REGISTRATION ARM (prereg §9 D10) — never pooled with the registered arms", "e3": { "namingAnswersInScope": 0, "removedNotTheAgent": 0, "byCode": { "status-correct": 0, "status-absent": 0, "status-wrong": 0, "UNCODED": 0 }, "inChoiceQuestions": 0, "clinicallyMaterial_absentOrWrong_inChoice": 0, "allCodesProvisional": true, "byAgent": { "sab-142": 0, "mtx-101": 0, "retogatein": 0, "crg-002": 0, "ct-868": 0, "hdv-insulin-lispro": 0, "gzr33": 0, "prv-101": 0, "cnty-813": 0, "tipifarnib": 0 }, "outOfScopeContext": {} }, "e3i": { "exploratory": true, "namings": 112, "distinctAnswers": 85, "byAgent": { "sotagliflozin": 3, "tirzepatide": 28, "semaglutide": 81, "bcg": 0, "fenofibrate": 0 }, "byWindowAgent": { "before-v4": { "sotagliflozin": { "named": 3, "sampled": 3 }, "tirzepatide": { "named": 28, "sampled": 28 }, "semaglutide": { "named": 81, "sampled": 60 }, "bcg": { "named": 0, "sampled": 0 }, "fenofibrate": { "named": 0, "sampled": 0 } }, "before-v5": { "sotagliflozin": { "named": 0, "sampled": 0 }, "tirzepatide": { "named": 0, "sampled": 0 }, "semaglutide": { "named": 0, "sampled": 0 }, "bcg": { "named": 0, "sampled": 0 }, "fenofibrate": { "named": 0, "sampled": 0 } }, "during": { "sotagliflozin": { "named": 0, "sampled": 0 }, "tirzepatide": { "named": 0, "sampled": 0 }, "semaglutide": { "named": 0, "sampled": 0 }, "bcg": { "named": 0, "sampled": 0 }, "fenofibrate": { "named": 0, "sampled": 0 } }, "after": { "sotagliflozin": { "named": 0, "sampled": 0 }, "tirzepatide": { "named": 0, "sampled": 0 }, "semaglutide": { "named": 0, "sampled": 0 }, "bcg": { "named": 0, "sampled": 0 }, "fenofibrate": { "named": 0, "sampled": 0 } }, "post-cutoff": { "sotagliflozin": { "named": 0, "sampled": 0 }, "tirzepatide": { "named": 0, "sampled": 0 }, "semaglutide": { "named": 0, "sampled": 0 }, "bcg": { "named": 0, "sampled": 0 }, "fenofibrate": { "named": 0, "sampled": 0 } } }, "byCode": { "indication-stated": 18, "indication-absent": 39, "indication-wrong": 0, "not-a-t1d-use": 34, "not-the-agent": 0, "UNCODED": 0, "NOT-SAMPLED": 21 }, "scoredT1dNamings": 57, "scoredT1dDistinctAnswers": 46, "indicationNotStated_absentOrWrong": { "k": 39, "n": 57, "share": 0.6842, "wilson95": [ 0.5552, 0.79 ] }, "exploratoryMaterial_absentOrWrong_inChoice": 8 }, "nonProgrammeContext": { "zimislecel": 9, "baricitinib": 3, "verapamil": 1 } }, "e3": { "rows": [], "perEngineCycle": {}, "outOfScopeContextPerEngineCycle": {} }, "e3i": { "rows": [ { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q19", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 27, "sampled": true, "code": "indication-stated", "span": "- *Cons:* Not yet approved for T1D; potential for increased hypoglycemia risk.", "note": "", "sha256": "723868b16c0d266920543b5588c7bb7c7aba6e93b1f03566dc52f89ccd1118a4" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 17, "sampled": true, "code": "not-a-t1d-use", "span": "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , which suggests increasing availability of advanced t", "note": "Manufacturing news; not named as a T1D option.", "sha256": "5c71a3ac7b1ab26287a1671af89d1ef79dba38cd10d8c63d6a3e4eb4b3f4c632" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 38, "sampled": true, "code": "not-a-t1d-use", "span": "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide in Saudi Arabia , signaling improved accessibility and affordability going forward.", "note": "Manufacturing news inside a top-5 answer; not named as a T1D option.", "sha256": "454a621d44b441f30f27332e38b9a222f0c9eaf7e7fe7ef2ef880380173ab20a" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 22, "sampled": true, "code": "not-a-t1d-use", "span": "mples in Saudi market analyses include **NovoRapid**, **Levemir**, **Tresiba**, **Ozempic**, **Victoza**, and **Xultophy**.[14] | | **Sanofi** | Long-standing presence in Saudi Arab", "note": "Company product list; not framed as a T1D product.", "sha256": "2101fa2b7fd27d87433054cea413e6308cc6c7cb534e3e839a38977bdda53f7e" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 55, "sampled": true, "code": "indication-absent", "span": "conducted in Saudi Arabia in 2023 evaluated the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments in adults with T1D and overweight/obesity. The study found significant improvements in gl", "note": "Offered as a T1D adjunct; no statement that the use is unapproved.", "sha256": "f91439aa545316f82ee30827ca66d09af53c5709f8f0dcfeea77902d532bb48b" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 16, "sampled": true, "code": "not-a-t1d-use", "span": "etes treatment.[1][6] Among these, **Ozempic/Rybelsus/Mounjaro/Jardiance** are *not standard type 1 diabetes treatments*; they may be seen in Saudi pharmacies, but they are primarily type 2/weight-management m", "note": "Named to rule it out for T1D.", "sha256": "3fb02122b16b1f279b2b94f5aab3c01732957138f422291f7df7e8c19e2a4977" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 57, "sampled": true, "code": "not-a-t1d-use", "span": "etes treatment.[1][6] Among these, **Ozempic/Rybelsus/Mounjaro/Jardiance** are *not standard type 1 diabetes treatments*; they may be seen in Saudi pharmacies, but they are primarily type 2/weight-management m", "note": "Named to rule it out for T1D.", "sha256": "3fb02122b16b1f279b2b94f5aab3c01732957138f422291f7df7e8c19e2a4977" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q16", "choiceQuestion": false, "agent": "sotagliflozin", "sampleRank": 0, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "f25ad3a85ad822cf2214e2bef8a5c25cc01fcf3b64c5a81b2ab3c0d2662d7e48", "note": "", "sha256": "bf4202c02e1b2ad611369e5b020490ebcf7f3f6073ac285d922bb0543776bd90" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q16", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 26, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "aeca2dfb5a006f3fef74c1d62e1fbaffbbe560f0a0a21d715764255eaad11ca3", "note": "", "sha256": "bf4202c02e1b2ad611369e5b020490ebcf7f3f6073ac285d922bb0543776bd90" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 10, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "10f08b51f1c7e285fbd02b7b1a7d26d1e6add9434f85b1fa109a0d7f78783486", "note": "", "sha256": "bf4202c02e1b2ad611369e5b020490ebcf7f3f6073ac285d922bb0543776bd90" }, { "slug": "SA-C01", "date": "2026-08-24", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q03", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 14, "sampled": true, "code": "indication-absent", "span": "ective cohort study involving adults with T1D and overweight/obesity found that GLP-1 agonists, such as semaglutide and liraglutide, significantly improved glycemic control, reduced insulin requirements, and led to weight loss without incre", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "41a7edeeae6be26ae6e5e181a487c29cd60c9be9f6157bacff7d7482eadf9439" }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q41", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 3, "sampled": true, "code": "indication-stated", "span": "While primarily for type 2 diabetes, it may be prescribed off-label for type 1 diabetes under specific medical guidance. ([[local-pharmacy-30]]([local-pharmacy-30]/p005", "note": "", "sha256": "66751f3af3e9ee98afc68833bb7918cd0d99ed21795b70d07f8a346e80562c10" }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 40, "sampled": true, "code": "not-a-t1d-use", "span": "While primarily for type 2 diabetes, GLP-1 receptor agonists like semaglutide and dulaglutide are gaining rapid adoption in S", "note": "Named for its own indication (prescription growth).", "sha256": "19fc3dbc794ce2ef0f1d8f48ff4df3245e9c8c89fc1dd9c2dcaa3bced42d4661" }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 71, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "8ac02cdc049f9c5aa27469c86b3f17f51bb3c23129dd822ce4680b95f5b04773" }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 13, "sampled": true, "code": "not-a-t1d-use", "span": "s, Jardiance, and metformin** appear in Saudi pharmacy catalogs, but they are **not the core treatment for type 1 diabetes**; insulin remains essential.[1][3]", "note": "Named to rule it out for T1D.", "sha256": "52007d6072fca062e1bf5b3122856fbf62bdae1116436d689ef79707ee04c9a0" }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 9, "sampled": true, "code": "not-a-t1d-use", "span": "s, Jardiance, and metformin** appear in Saudi pharmacy catalogs, but they are **not the core treatment for type 1 diabetes**; insulin remains essential.[1][3]", "note": "Named to rule it out for T1D.", "sha256": "52007d6072fca062e1bf5b3122856fbf62bdae1116436d689ef79707ee04c9a0" }, { "slug": "SA-C02", "date": "2026-08-27", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q37", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 41, "sampled": true, "code": "indication-stated", "span": "ta show no significant hypoglycemia or DKA in a small retrospective cohort, but evidence is still off-label and not standard T1D therapy[8][11] | Popular for weight loss and adjunct use, but not fi", "note": "", "sha256": "87597d083de54d12a0c992bba611bb2fdfb9a2f30c3ae628be8951f8c86100b3" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 4, "sampled": true, "code": "indication-stated", "span": "Clinical trials are ongoing to assess their efficacy and safety in this context. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-118]/p002", "note": "", "sha256": "cd52719dad6362c51c10a54b8b88ccacf266294af3b7be3171f6e376cf0fea93" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q22", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 73, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "65724b2c6a5d0a53abfd2aff2a21cc3b9b5bac7e1f442e612ae4c6011627be4e" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q33", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 62, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "00667ac42f31c91f2417807a2e82cf5aa361c322fb698844c31582f63ab62b74" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 30, "sampled": true, "code": "indication-absent", "span": "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive therapy in adults with T1D who are overweight or obese. A retrospective cohort study conducted be", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "6d37e9ef7196d4a8181a696e18daac98a5eae0c30c84f1160d98252083170e5c" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 23, "sampled": true, "code": "not-a-t1d-use", "span": "sus, Trulicity, Saxenda** | These are listed in Saudi pharmacies, but they are *not standard type 1 diabetes treatment*; they are more relevant to type 2 diabetes or weight management.[1][12] |", "note": "Named to rule it out for T1D.", "sha256": "4b37fb37d8236141c6bfec6d19134171dad2e397269dc108fbb098d11b167823" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 33, "sampled": true, "code": "not-a-t1d-use", "span": "sus, Trulicity, Saxenda** | These are listed in Saudi pharmacies, but they are *not standard type 1 diabetes treatment*; they are more relevant to type 2 diabetes or weight management.[1][12] |", "note": "Named to rule it out for T1D.", "sha256": "4b37fb37d8236141c6bfec6d19134171dad2e397269dc108fbb098d11b167823" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q02", "choiceQuestion": true, "agent": "tirzepatide", "sampleRank": 10, "sampled": true, "code": "indication-absent", "span": "*: Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks, with combined notable weight reductions driving rapid u", "note": "Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status.", "sha256": "827ad3cb2dc3aa9e0f25bbde276b9ce48ae7db843feb593d1eac55d5ef09fe64" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q02", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 50, "sampled": true, "code": "indication-absent", "span": "- **GLP-1 Receptor Agonists**: Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks,", "note": "Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status.", "sha256": "827ad3cb2dc3aa9e0f25bbde276b9ce48ae7db843feb593d1eac55d5ef09fe64" }, { "slug": "SA-C03", "date": "2026-08-30", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q03", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 75, "sampled": false, "code": "NOT-SAMPLED", "span": "[Gemini answer text withheld]", "spanSha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "note": "", "sha256": "0ca53c5d812d43ed862f740b9af2ebf11f92dce806a1841d875d3379c68698de" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 19, "sampled": true, "code": "indication-stated", "span": "Clinical trials are ongoing to assess its efficacy and safety in this context. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-118]/p002", "note": "", "sha256": "d91124520c8bfcb4654ff29de153f112d6306c4171bdf058602a631489d94264" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 29, "sampled": true, "code": "indication-absent", "span": "ted in Saudi Arabia between January 2022 and February 2023 evaluated the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive therapy in adults with T1D and overweight/obesity. The study found that GLP-1 agonists signif", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "dee751c82f5385da218822f1999fbcfb16a459880f49fe281db9bdb4ab2313dd" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 27, "sampled": true, "code": "not-a-t1d-use", "span": "iance, Mounjaro, and Glucophage** are listed by Saudi pharmacies, but these are primarily **type 2 diabetes** treatments and are *not* the core treatment for type 1 diabetes.[2] A Saudi indication document also", "note": "Named to rule it out for T1D.", "sha256": "c49e75ef64a7c37807934e9b7a26e39e90579b91b9ff2970ea4b1a18181e6034" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 53, "sampled": true, "code": "not-a-t1d-use", "span": "iance, Mounjaro, and Glucophage** are listed by Saudi pharmacies, but these are primarily **type 2 diabetes** treatments and are *not* the core treatment for type 1 diabetes.[2] A Saudi indication document also", "note": "Named to rule it out for T1D.", "sha256": "c49e75ef64a7c37807934e9b7a26e39e90579b91b9ff2970ea4b1a18181e6034" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q31", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 15, "sampled": true, "code": "indication-absent", "span": "- Out-of-pocket burden deters uptake even when medications like Tirzepatide show efficacy", "note": "Named as a medication in a T1D coverage answer; no status statement.", "sha256": "ddb1aa795779b41df3c3c25a5864a81d06a72077db0c2e1410c8543c1152bd29" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q02", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 12, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "8be1d08b91d5e2f12b318136a034f23ef61c852abb10e2ecd5fa1b7cc0213ca2", "note": "", "sha256": "be797551a5e58dee22114d333b10f7fc04b37cf0f8672c3935f3c7889fe3ff21" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q37", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 63, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "802b318ab9d1f71e675f9d152e854570958629404086a8d27a775d64956870d5" }, { "slug": "SA-C04", "date": "2026-09-01", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q30", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 15, "sampled": true, "code": "indication-absent", "span": "nfections**.[2] - In a Saudi retrospective cohort of adjunct **GLP-1 agonists**—mostly **semaglutide** and some **liraglutide**—HbA1c improved by **0.84%**, time-in-range improved by **15%**,", "note": "Adjunct cohort result in a T1D answer; no status statement.", "sha256": "de000744d285df8b986427c4cd3f8ecdfbeb9c4260e3bf22a967a1d2ef7a93bb" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 68, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "804a3cfc4957a061d568ce2e6fe17f1a9f1dd23cf193653ad975fa924ce242ce" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 0, "sampled": true, "code": "indication-absent", "span": "orted local manufacturing/supply activity in KSA.[4][6][11] | | **Eli Lilly** | Humalog, Trulicity, Mounjaro | Major insulin player with strong global diabetes reputation and KSA market presence.[1]", "note": "Listed under \"Main products relevant to type 1 diabetes\"; no status statement.", "sha256": "6d039c4c86282115629b4a96f6bb38f0f1b2aff16822e699a5207fab8cc6e300" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 8, "sampled": true, "code": "indication-absent", "span": "diabetes | Why they matter for a KSA buyer | |---|---|---| | **Novo Nordisk** | NovoRapid, Levemir, Tresiba, Ozempic, Victoza, Xultophy | Widely cited as a KSA leader; strong insulin portfolio and Saudi-spe", "note": "Listed under \"Main products relevant to type 1 diabetes\"; no status statement.", "sha256": "6d039c4c86282115629b4a96f6bb38f0f1b2aff16822e699a5207fab8cc6e300" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 18, "sampled": true, "code": "indication-absent", "span": "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive therapy in adults with T1D who are overweight or obese. Findings indicate that GLP-1 agonists can", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "fca1265a734eea68e976cb758cfdfa5677773c6f97758b22d737ab46e60293f6" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q16", "choiceQuestion": false, "agent": "sotagliflozin", "sampleRank": 1, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "6466c6e333d6f2d57fbe309cc8a2d884dfc81c2a0d7e8e588ad82fe40b3a2aa9", "note": "", "sha256": "c70872eddc0052a94e6302e2c4b8e77522c408a1497fc30eae392400518d2d1c" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q02", "choiceQuestion": true, "agent": "tirzepatide", "sampleRank": 11, "sampled": true, "code": "indication-absent", "span": "th access and resources, oral semaglutide trimmed HbA1c by 3.1% at 6 months and tirzepatide enabled 64.1% of patients to reach targets within 40 weeks , though premium pricing limits access even though GLP-1", "note": "Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status.", "sha256": "57529322106a5b02af211588a590385bedc2a319f9171900cc8b874653da0c9d" }, { "slug": "SA-C05", "date": "2026-09-03", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q02", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 42, "sampled": true, "code": "indication-absent", "span": "For patients with access and resources, oral semaglutide trimmed HbA1c by 3.1% at 6 months and tirzepatide enabled 64.1% of patients to reach targets within 40 weeks ,", "note": "Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status.", "sha256": "57529322106a5b02af211588a590385bedc2a319f9171900cc8b874653da0c9d" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 47, "sampled": true, "code": "indication-absent", "span": ") **GLP-1 Receptor Agonists** GLP-1 receptor agonists, such as semaglutide, are emerging adjunctive treatments for T1D. They help manage blood sugar levels and may support weight loss. Clinical studies in Sau", "note": "\"Emerging\" and past studies are not a status statement (S3).", "sha256": "2ddf72fe446c9e86403249f3e08c9564d5a8604d065b29221dc4733e4224349f" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 2, "sampled": true, "code": "indication-absent", "span": "ablished KSA presence and broad diabetes footprint.[9][2] | | **Eli Lilly** | **Humalog, Trulicity, Mounjaro** | Important in insulin and advanced diabetes therapy; strong tertiary-hospital relevanc", "note": "Listed under \"Products most relevant to type 1 diabetes\"; no status statement.", "sha256": "a9f8f7b3600c6dd5f83c759939112935b086736d63925226f00e77593a22e917" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 70, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "a9f8f7b3600c6dd5f83c759939112935b086736d63925226f00e77593a22e917" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 21, "sampled": true, "code": "indication-absent", "span": "A 2023 study in Saudi Arabia evaluated the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments in adults with T1D and obesity. The findings indicated significant improvements in glycem", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "665d17915d6686715aa0f2fd9870a48d52cdf1a31281b6ac07235dcba4b072cb" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q32", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 56, "sampled": true, "code": "not-a-t1d-use", "span": "Additionally, Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide in Saudi Arabia , which is expanding treatment options.", "note": "Manufacturing news; not named as a T1D option.", "sha256": "6a705e3e0a3bfa38034653ddc06be84704d1d5072d2ce0db5b0931691349703e" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 19, "sampled": true, "code": "not-a-t1d-use", "span": "Rybelsus, Jardiance, and Synjardy** are sold in Saudi pharmacies, but these are primarily for type 2 diabetes/weight-related indications, not standard type 1 insulin replacement.[2][12][17]", "note": "Named to rule it out for T1D.", "sha256": "8ace05ec035078c42bd610d47bc8b5d656b5f2e6fe7f1a53801ac28c896d47ad" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 72, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "8ace05ec035078c42bd610d47bc8b5d656b5f2e6fe7f1a53801ac28c896d47ad" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q11", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 22, "sampled": true, "code": "not-a-t1d-use", "span": "- **Ozempic, Rybelsus, Mounjaro, and similar medicines are not standard treatment for type 1 diabetes**; they appear in Saudi diabetes pharmacy listings, but they are mainly used for type 2 d", "note": "Named to rule it out for T1D.", "sha256": "c44c1410ed7b86ea3a59991f21b615e10687db36af7bd2ae53521fc1597263a0" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q11", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 78, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "c44c1410ed7b86ea3a59991f21b615e10687db36af7bd2ae53521fc1597263a0" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q03", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 49, "sampled": true, "code": "indication-absent", "span": "LP-1 Receptor Agonists**: A retrospective cohort study in Saudi Arabia compared GLP-1 receptor agonists (e.g., semaglutide) with SGLT2 inhibitors in T1D patients over 12 months. The study found that GLP-1 receptor agonists led to significan", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "96f1a472c829619f5f091b6150bd7358b0c70bce4fb5faf104cc282a53145195" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q30", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 18, "sampled": true, "code": "indication-absent", "span": "For patients taking GLP-1-RA drugs like semaglutide and tirzepatide, the five-year risk of major cardiovascular events and end-stage kidney disease were redu", "note": "Outcome data in a T1D answer without population or status.", "sha256": "9d64c9e05298e9d10eb114ca91555e0fa7b420e05ffda6887062630e348de86d" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q30", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 67, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "9d64c9e05298e9d10eb114ca91555e0fa7b420e05ffda6887062630e348de86d" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q34", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 11, "sampled": true, "code": "not-a-t1d-use", "span": "[Gemini answer text withheld]", "spanSha256": "3ef781223ab7dbbc227f59c533b1101e4ef6577e9aaaa9bc60a502afa9a6a659", "note": "Named for its own indication, to illustrate an access pathway.", "sha256": "86f38df714e95c72a161c862e03e2c58f12ebbb0298a49b82f11c8a8c424b544" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q37", "choiceQuestion": true, "agent": "tirzepatide", "sampleRank": 14, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "2c581c655c3b034688b567131fe0d1e6701ae27a09b3d767f5c231ee2d17f49e", "note": "", "sha256": "4a643c569fb8cfed1099677ed1e595b17f863383477f27d685fb9b08038492e2" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q37", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 13, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "2c581c655c3b034688b567131fe0d1e6701ae27a09b3d767f5c231ee2d17f49e", "note": "", "sha256": "4a643c569fb8cfed1099677ed1e595b17f863383477f27d685fb9b08038492e2" }, { "slug": "SA-C06", "date": "2026-09-08", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q30", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 35, "sampled": true, "code": "indication-absent", "span": "nsumer-friendly” upgrade for everyone.[1] - **Semaglutide** and **liraglutide** were the main GLP-1 agonists reported in a Saudi retrospective cohort, but these are *adjuncts* and not standard replacement therapy for type 1 diabetes.[6] -", "note": "\"Not standard replacement therapy\" is not a status statement.", "sha256": "cd17092f4e3e677c8c6a7fe101366e642f5c55a864ecd3166e54bbeb225cb3cc" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 31, "sampled": true, "code": "indication-stated", "span": "Clinical trials are ongoing in Saudi Arabia to assess their efficacy and safety. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-118]/p001", "note": "", "sha256": "4941e0d2983891a667ac23936a57763278752626fca168a68f6b014523b1b6f9" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q33", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 66, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "966f4c5cff04585907c4aac4f1f69f90fb9b1403d8b8eac2a4f431151500521f" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q27", "choiceQuestion": true, "agent": "tirzepatide", "sampleRank": 25, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "389b1ba936f846682416732511933b9dfc20a537c2e9d172ad30b2facead8070", "note": "", "sha256": "ff7ed4bc7cc9f56ae9798bc47bd0f180ce9a43ce5cc74923ca6d9a648f66c447" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 0, "sampled": true, "code": "indication-stated", "span": "[Gemini answer text withheld]", "spanSha256": "389b1ba936f846682416732511933b9dfc20a537c2e9d172ad30b2facead8070", "note": "", "sha256": "ff7ed4bc7cc9f56ae9798bc47bd0f180ce9a43ce5cc74923ca6d9a648f66c447" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 24, "sampled": true, "code": "indication-absent", "span": "Xultophy** from Novo Nordisk; **Lantus, Toujeo, and Soliqua** from Sanofi; and **Humalog, Trulicity, and Mounjaro** from Eli Lilly.[7] That said, for **type 1 diabetes**, the core products are the **insulins** rather tha", "note": "Listed among the most important products \"for type 1 diabetes specifically\", then qualified as mainly type 2; no status statement.", "sha256": "98f4fcde7e67a914017a13a05de417c36986a17c3c0a6f18e97edee46073a7a8" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 74, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "98f4fcde7e67a914017a13a05de417c36986a17c3c0a6f18e97edee46073a7a8" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 46, "sampled": true, "code": "indication-absent", "span": "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments for adults with Type 1 diabetes who are overweight or obese. These medications have shown", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "d147019defa12c4130427f76f09932d109e9bec4d1309849889c56a0e57690c2" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 6, "sampled": true, "code": "not-a-t1d-use", "span": "treatment** in Saudi Arabia, the most relevant consumer choice is **insulin**, not GLP-1 drugs like Ozempic, Mounjaro, or Rybelsus, because people with type 1 diabetes need daily insulin to survive.[4][16] In the Saudi m", "note": "Named to rule it out for T1D.", "sha256": "0a41fb8b88c03264fadce51be91db42cfda36e222d2d9890288b828fb721015a" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 61, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "0a41fb8b88c03264fadce51be91db42cfda36e222d2d9890288b828fb721015a" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q23", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 69, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "0b85d114f1245a6341b080a4c3240afff0350eade6381c72fa974be3e6729dfb" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q38", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 45, "sampled": true, "code": "not-a-t1d-use", "span": "As of February 2026, generic semaglutide (Ozempic) received SFDA approval in Saudi Arabia , making GLP-1 therapy more accessible.", "note": "Market fact; not named as a T1D option.", "sha256": "9eff6aed99954a5a1047bf515bafe2384ac8f1eb634256610868473b65b45972" }, { "slug": "SA-C07", "date": "2026-09-10", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q37", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 59, "sampled": true, "code": "indication-stated", "span": "cts and very few serious events reported in the Saudi cohort; however, they are still off-label adjuncts for T1D in many settings.[7][8] | **Popular in Saudi market**: a Saudi T1D cohort used mostly **s", "note": "", "sha256": "289a7e210ac9b03c05417b5ec16413f2603367803707f977597f791343015d87" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 5, "sampled": true, "code": "not-a-t1d-use", "span": "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , indicating movement toward local manufacturing to im", "note": "Manufacturing news; not named as a T1D option.", "sha256": "f8b5b6abdbb426913b9b0772452ba942406b8febfeef1808b08dd140a8b3f3a7" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 23, "sampled": true, "code": "indication-absent", "span": "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments in adults with Type 1 diabetes who are overweight or obese. These medications have shown", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "f29bc85e567b10b137c29f07c6c04e33f9dc5476f715adeee7f99abdb0cba5f3" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-f01", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 21, "sampled": true, "code": "not-a-t1d-use", "span": "[Gemini answer text withheld]", "spanSha256": "478dbf965f05f6f2da0048f091d31c01d717049c1d16c31c16ed27da65a91f6b", "note": "Listed among drugs for managing diabetes in contrast to Tzield; not named as a T1D option.", "sha256": "9a2378339a5a90460be3fb7ab7cf9aa494d66d8c83a42d544a816a770f50b80a" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 17, "sampled": true, "code": "not-a-t1d-use", "span": "market, such as **Ozempic**, **Mounjaro**, **Jardiance**, and **Rybelsus**, are primarily type 2 diabetes products; they are *not* the core treatment for type 1 diabetes.[2][11][14][16] - **How to think a", "note": "Named to rule it out for T1D.", "sha256": "cabbf5210f8bfc91db1e1035deb2c3ee2bd83d57dcd512ef910ebe6941854ba2" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 7, "sampled": true, "code": "not-a-t1d-use", "span": "market, such as **Ozempic**, **Mounjaro**, **Jardiance**, and **Rybelsus**, are primarily type 2 diabetes products; they are *not* the core treatment for type 1 diabetes.[2][11][14][16]", "note": "Named to rule it out for T1D.", "sha256": "cabbf5210f8bfc91db1e1035deb2c3ee2bd83d57dcd512ef910ebe6941854ba2" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 51, "sampled": true, "code": "not-a-t1d-use", "span": "[Gemini answer text withheld]", "spanSha256": "fd2bea44ba016fe0e27c53e0704bfb37eb471099e7c521eabc4bcfd98a9d88bb", "note": "Market trend; named for its own indication.", "sha256": "505fed915bcdb32afad8199bef2ebd1bfc46e481084a009e886dc12b92ba6831" }, { "slug": "SA-C08", "date": "2026-09-14", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q30", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 37, "sampled": true, "code": "indication-absent", "span": "consumer-level caution: - Some newer **adjunct drugs** studied in Saudi Arabia, such as **empagliflozin** or **semaglutide**, may improve glucose-related measures, but they are **not standard core treatment for T1D", "note": "\"Not standard core treatment\" is not a status statement.", "sha256": "314d3fc5eec3dd1065d8617ce1be2ab8b34c9b75f7d768ddc9be409fdddcf54d" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 28, "sampled": true, "code": "indication-absent", "span": "or Agonists (e.g., Semaglutide)** GLP-1 receptor agonists, such as semaglutide, are used to manage blood sugar levels in T1D patients. They can help reduce appetite and support weight loss, which is beneficial for overall h", "note": "Presented as used in T1D; no status statement.", "sha256": "6d57b6d260f683241a2824519e0ef2cbe69ea6e4a9790f12cc56523c6d0f6495" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q16", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 1, "sampled": true, "code": "indication-absent", "span": "### **Tirzepatide (Mounjaro)** - Tirzepatide is expected to become increasingly available in Saudi Arabia and has shown promising glycemic control and weight loss - Tirzepatide is", "note": "Heading in a T1D options answer; no status statement.", "sha256": "bfa92be7626a82d352a3639ea1151c3ca5c4a332c46b21171df2163c9383ed28" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 25, "sampled": true, "code": "indication-absent", "span": "ovy)** - Semaglutide was the largest segment with 73.9% revenue share in 2025 - Semaglutide is the most widely used GLP-1 RA in Saudi Arabia, accounting for over 70% of all public-sector market share - Growing availability but les", "note": "Heading in a T1D options answer; no status statement.", "sha256": "bfa92be7626a82d352a3639ea1151c3ca5c4a332c46b21171df2163c9383ed28" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 12, "sampled": true, "code": "not-a-t1d-use", "span": "**, insulin remains the core treatment, while some of those other medicines are more relevant to type 2 or other indications.[1][2][12][18]", "note": "Named for its own indication.", "sha256": "3428432b5dd5eeb2d7f23ca35e9aa72b086c45382dc23456d099caa5107ca755" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 79, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "3428432b5dd5eeb2d7f23ca35e9aa72b086c45382dc23456d099caa5107ca755" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q23", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 2, "sampled": true, "code": "not-a-t1d-use", "span": "Ozempic carries a \"Limitations of Use\" statement: \"Not indicated for use in type 1 diabetes mellitus or treatment of diabetic ketoacidosis.\"", "note": "Named to rule it out for T1D, quoting the label limitation of use.", "sha256": "cddb6d5b7e1ca58ed36622b42a8b10b9d7cbe0b4a3d9c7119d2be8ef6203063a" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q30", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 8, "sampled": true, "code": "indication-absent", "span": "available in Saudi Arabia, oral semaglutide trims HbA1c by 3.1% at 6 months and tirzepatide enables 64.1% of patients to reach targets within 40 weeks, with notable weight reductions .", "note": "Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status.", "sha256": "5e1c5b781ab4a52c62255d5bbaa0bf78204510b7a113268f3330fff89f327244" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q30", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 20, "sampled": true, "code": "indication-absent", "span": "For newer treatments available in Saudi Arabia, oral semaglutide trims HbA1c by 3.1% at 6 months and tirzepatide enables 64.1% of patients to reach targets within 40 weeks, w", "note": "Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status.", "sha256": "5e1c5b781ab4a52c62255d5bbaa0bf78204510b7a113268f3330fff89f327244" }, { "slug": "SA-C09", "date": "2026-09-16", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q15", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 64, "sampled": false, "code": "NOT-SAMPLED", "span": "[Gemini answer text withheld]", "spanSha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "note": "", "sha256": "9e46f5eaf4398f6c5d9e2ad3202dc286f42e72389997432399cf111009a48158" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 43, "sampled": true, "code": "indication-stated", "span": "ww.nature.com/articles/s41574-025-01154-4?utm_source=openai) **GLP-1 Agonists** While primarily approved for type 2 diabetes, GLP-1 agonists like semaglutide are being explored for T1D management. Clinical trials a", "note": "", "sha256": "1f70ff6ff8645bb9fcc1cf592d55bf6b936ccdfb74d740229b28b550de5edcf6" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 1, "sampled": true, "code": "not-a-t1d-use", "span": "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , and Sanofi's collaboration with Sudair Pharma Compan", "note": "Manufacturing news; not named as a T1D option.", "sha256": "b2657f9cbe34a42d9dc2311fe0c41d64abea29ff9850841b660b239c8537fe74" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 7, "sampled": true, "code": "not-a-t1d-use", "span": "with strong tender depth and long-acting analog strength.[10] - **Eli Lilly:** Humalog, Trulicity, Mounjaro; described as a leader with rapid uptake and tertiary-hospital reach.[10] - **Medtronic:*", "note": "Company product list; not framed as a T1D product.", "sha256": "b0908f5869d317edae5eb8137e6064a8d744db02b4f27249fb681e9926e81d6a" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 3, "sampled": true, "code": "not-a-t1d-use", "span": "**Best-known products in the Saudi market** - **Novo Nordisk:** NovoRapid, Levemir, Ozempic; the company is described as a leader in Saudi diabetes care.[10] - **Sanofi:** Lantus, T", "note": "Company product list; not framed as a T1D product.", "sha256": "b0908f5869d317edae5eb8137e6064a8d744db02b4f27249fb681e9926e81d6a" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 52, "sampled": true, "code": "indication-absent", "span": "The findings indicated significant improvements in glycemic control, weight reduction, and insulin requirements, suggesting a promising role for GLP-1 agonists in T1D management. ([diabetesjournals.org](https://diabetesjournals.org/diabetes", "note": "Offered as a T1D adjunct; no status statement.", "sha256": "d2e253a7a628ed36f67cae6e8ce3d0a72c933dcddba244d3da21473966546c4e" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q05", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 6, "sampled": true, "code": "not-a-t1d-use", "span": "[Gemini answer text withheld]", "spanSha256": "03b964ff468ed9416ad6ad9ac575516f3e6acbc355d3fbef63a4982d5d4c34bf", "note": "Named to rule it out for T1D.", "sha256": "8136e39fa5ca0549d9d35f796c8bdd07d3039bf114707a3039dccf5d37e7db3a" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q16", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 4, "sampled": true, "code": "indication-absent", "span": "Once-weekly insulin icodec promises higher adherence, and local evidence shows oral semaglutide and tirzepatide are delivering significant HbA1c reductions and weight loss benefits.", "note": "In a T1D answer; no status statement.", "sha256": "7b1bbe963054743d1fa36d0d0abbddf21146987030646f86c3dd4b5b4af23580" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 24, "sampled": true, "code": "indication-absent", "span": "Once-weekly insulin icodec promises higher adherence, and local evidence shows oral semaglutide and tirzepatide are delivering significant HbA1c reductions and weight loss benefits.", "note": "\"Not first-line\" is not a status statement.", "sha256": "7b1bbe963054743d1fa36d0d0abbddf21146987030646f86c3dd4b5b4af23580" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q03", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 44, "sampled": true, "code": "indication-absent", "span": "- **GLP-1 Receptor Agonists:** Medications like semaglutide and liraglutide have been evaluated for their efficacy in T1D management. A multicenter study in Riyadh found that adding GLP-1 receptor agonists to insulin thera", "note": "Past evaluation is not a status statement (S3).", "sha256": "82772f1aa4ba46fc5d6c581ce370a563c188f5fcd9adbf1490c5716411bc6723" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q01", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 58, "sampled": true, "code": "not-a-t1d-use", "span": "generic semaglutide Ozempic in Saudi Arabia, enabling commercialization of the diabetes and weight-management treatment .", "note": "Approval news; not named as a T1D option.", "sha256": "5f8fbf2f7c991340f036585cbc7c69af1a663a480e2d4c8e752e4d6d6b304751" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q14", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 48, "sampled": true, "code": "not-a-t1d-use", "span": "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia, aligning with national priorities .", "note": "Manufacturing news; not named as a T1D option.", "sha256": "e17bc4a12b83155fc97e81b3259150134d816295f7841f7e7ca8fb473c7bce7e" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q03", "choiceQuestion": false, "agent": "sotagliflozin", "sampleRank": 2, "sampled": true, "code": "indication-absent", "span": "nied by weight loss and reduction of daily insulin doses with SGLT2 inhibitors (dapagliflozin and sotagliflozin) in combination with insulin.", "note": "Completed phase III evidence in T1D; no status statement.", "sha256": "23c321e8c8959f96976f73592302dd657c33ce37319610ae937e342c8de5a8dd" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q03", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 80, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "23c321e8c8959f96976f73592302dd657c33ce37319610ae937e342c8de5a8dd" }, { "slug": "SA-C10", "date": "2026-09-21", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q37", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 39, "sampled": true, "code": "indication-absent", "span": "If you mean **medicine add-ons to insulin**, the **safest-looking adjunctive option in Saudi data is GLP-1 receptor agonists** (for example, **semaglutide** and **liraglutide**), because Saudi studies reported **no", "note": "Offered as the safest T1D add-on; no status statement.", "sha256": "f41f944dea1c537f92390354acff1cdad2e2847b4306b02acec186168b9fac5f" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 34, "sampled": true, "code": "indication-stated", "span": "Clinical trials are ongoing in Saudi Arabia to assess its efficacy alongside insulin therapy. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-170]/p001", "note": "", "sha256": "4804367774867b3939fd86f526a873990a8fdb173ee5827edd110def5daa31eb" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q27", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 16, "sampled": true, "code": "not-a-t1d-use", "span": "is also a reported **first generic semaglutide** launch in Saudi Arabia, but **semaglutide is not a standard Type 1 diabetes treatment**, so it should not be counted among the top Type 1 options for this question.[19]", "note": "Named to rule it out for T1D.", "sha256": "d019d21c7b108970133a545d550cd22f3dded305b517c8762d077fca7dec254c" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 5, "sampled": true, "code": "not-a-t1d-use", "span": "**Mounjaro** and **Trulicity** are also associated with Lilly, though these are more relevant to diabetes management overall than type 1 specifically.[11] - **AstraZeneca:** **Forxiga** appears in Saudi market coverage, but this is mainly", "note": "Named for its own indication.", "sha256": "e70878ab2c04eaeccba1e9258c845e8b51499c405b1fea736d52c3f933e69872" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q41", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 65, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "e70878ab2c04eaeccba1e9258c845e8b51499c405b1fea736d52c3f933e69872" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "openai", "promptId": "sa-q16", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 54, "sampled": true, "code": "indication-absent", "span": "A retrospective cohort study conducted in Saudi Arabia between January 2022 and February 2023 found that adding semaglutide to insulin therapy resulted in a significant reduction in HbA1c levels, improved time in range (TIR), and weight los", "note": "Heading \"Semaglutide\" in a T1D options answer; no status statement.", "sha256": "fe0b4183a0925f4d8db99ec9ece6d8161c370986e00f69c19ed12ac32e8bf34b" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q12", "choiceQuestion": true, "agent": "semaglutide", "sampleRank": 36, "sampled": true, "code": "indication-absent", "span": "ely available, established clinical experience - **Alternative/Complementary**: GLP-1 therapies like semaglutide (now with generic approval) for enhanced glycemic control and metabolic benefits - **Access**: Utilize public hospita", "note": "Offered as a T1D alternative citing the generic approval, which a reader may take as approval for T1D; not coded wrong because no T1D indication is claimed.", "sha256": "b64378fa12bab92a3e571058be39b459e7f8d7d75ef91498d863924cf4d97b76" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 20, "sampled": true, "code": "not-a-t1d-use", "span": "sk and Sanofi insulin brands**, with **Eli Lilly** also clearly present through **Humalog** and **Mounjaro** in Saudi market listings.[1][2][12][15] Saudi market research also identifies **Novo Nordisk, Sanofi, and Eli Lill", "note": "Company presence; not named as a T1D option.", "sha256": "7db2c0cc198618c8d1d9ec977de1a71cb94507ceb88631cae3be831d0b853bfa" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q09", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 76, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "7db2c0cc198618c8d1d9ec977de1a71cb94507ceb88631cae3be831d0b853bfa" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q30", "choiceQuestion": false, "agent": "tirzepatide", "sampleRank": 9, "sampled": true, "code": "indication-absent", "span": "lore newer medications, recent research on GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro) shows the five-year risk of major cardiovascular events and the risk of end-stage kidney", "note": "Outcome data in a T1D answer without population or status.", "sha256": "9868fc493ec1e36d90559c4c66a8b8e317a8ac39425a230814f0866b965d7387" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "anthropic", "promptId": "sa-q30", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 26, "sampled": true, "code": "indication-absent", "span": "lore newer medications, recent research on GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro) shows the five-year risk of major cardiovascular events and the risk of end-stage kidney", "note": "Outcome data in a T1D answer without population or status.", "sha256": "9868fc493ec1e36d90559c4c66a8b8e317a8ac39425a230814f0866b965d7387" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "google", "promptId": "sa-q04", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 77, "sampled": false, "code": "NOT-SAMPLED", "span": "[Gemini answer text withheld]", "spanSha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "note": "", "sha256": "88aa63dd8baeddb7809ddc59973fd87299520c4bc6d251c45ede63cb1b19d459" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q20", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 32, "sampled": true, "code": "indication-absent", "span": "eceptor agonists** have mainly **GI side effects** such as nausea and vomiting; Saudi real-world data on semaglutide reported GI problems as the most common adverse effect, and other Saudi studies similarly", "note": "Side effects of a T1D adjunct; no status statement.", "sha256": "bd33a1fc8d91113806f682844bae8f4e2a2bb4ee029f5883e7781aca6bc8846b" }, { "slug": "SA-C11", "date": "2026-09-26", "window": "before-v4", "engineVersion": 4, "engine": "perplexity", "promptId": "sa-q03", "choiceQuestion": false, "agent": "semaglutide", "sampleRank": 60, "sampled": false, "code": "NOT-SAMPLED", "span": "", "note": "", "sha256": "0baade85a153bec6b92e75e84ba93e8b5943918b7a3f39c0ac39dc3a74be3db3" } ], "perEngineCycle": { "SA-C01": { "openai": { "indication-stated": 1, "indication-absent": 2 }, "anthropic": { "not-a-t1d-use": 2 }, "perplexity": { "not-a-t1d-use": 3 }, "google": { "indication-stated": 3 } }, "SA-C02": { "openai": { "indication-stated": 1, "NOT-SAMPLED": 1 }, "anthropic": { "not-a-t1d-use": 1 }, "perplexity": { "not-a-t1d-use": 2, "indication-stated": 1 } }, "SA-C03": { "openai": { "indication-stated": 1, "indication-absent": 1 }, "anthropic": { "NOT-SAMPLED": 2, "indication-absent": 2 }, "perplexity": { "not-a-t1d-use": 2 }, "google": { "NOT-SAMPLED": 1 } }, "SA-C04": { "openai": { "indication-stated": 1, "indication-absent": 1 }, "perplexity": { "not-a-t1d-use": 2, "NOT-SAMPLED": 1, "indication-absent": 1 }, "anthropic": { "indication-absent": 1 }, "google": { "indication-stated": 1 } }, "SA-C05": { "openai": { "NOT-SAMPLED": 1, "indication-absent": 1 }, "perplexity": { "indication-absent": 2 }, "google": { "indication-stated": 1 }, "anthropic": { "indication-absent": 2 } }, "SA-C06": { "openai": { "indication-absent": 3 }, "perplexity": { "indication-absent": 2, "NOT-SAMPLED": 3, "not-a-t1d-use": 2 }, "anthropic": { "not-a-t1d-use": 1, "indication-absent": 1, "NOT-SAMPLED": 1 }, "google": { "not-a-t1d-use": 1, "indication-stated": 2 } }, "SA-C07": { "openai": { "indication-stated": 1, "NOT-SAMPLED": 1, "indication-absent": 1 }, "google": { "indication-stated": 2 }, "perplexity": { "indication-absent": 1, "NOT-SAMPLED": 2, "not-a-t1d-use": 1, "indication-stated": 1 }, "anthropic": { "NOT-SAMPLED": 1, "not-a-t1d-use": 1 } }, "SA-C08": { "anthropic": { "not-a-t1d-use": 1 }, "openai": { "indication-absent": 1 }, "google": { "not-a-t1d-use": 2 }, "perplexity": { "not-a-t1d-use": 2, "indication-absent": 1 } }, "SA-C09": { "openai": { "indication-absent": 1 }, "anthropic": { "indication-absent": 4, "not-a-t1d-use": 1 }, "perplexity": { "not-a-t1d-use": 1, "NOT-SAMPLED": 1 }, "google": { "NOT-SAMPLED": 1 } }, "SA-C10": { "openai": { "indication-stated": 1, "indication-absent": 2 }, "anthropic": { "not-a-t1d-use": 3, "indication-absent": 3, "NOT-SAMPLED": 1 }, "perplexity": { "not-a-t1d-use": 2, "indication-absent": 1 }, "google": { "not-a-t1d-use": 1 } }, "SA-C11": { "openai": { "indication-stated": 1, "indication-absent": 1 }, "perplexity": { "not-a-t1d-use": 3, "NOT-SAMPLED": 3, "indication-absent": 1 }, "anthropic": { "indication-absent": 3 }, "google": { "NOT-SAMPLED": 1 } } } }, "nonProgrammeContextPerEngineCycle": { "zimislecel": { "SA-C01": { "google": 1 }, "SA-C03": { "google": 2 }, "SA-C05": { "google": 1 }, "SA-C06": { "perplexity": 2 }, "SA-C07": { "perplexity": 1 }, "SA-C08": { "anthropic": 1 }, "SA-C11": { "google": 1 } }, "baricitinib": { "SA-C02": { "google": 1 }, "SA-C09": { "google": 1 }, "SA-C11": { "google": 1 } }, "verapamil": { "SA-C03": { "google": 1 } } } }